Tehran -Iranian knowledge -based companies have developed new methods for synthesizing TECHNETIUM (99MTC) TilmanoCept, a radioactive drug diagnostic imaging agent used to determine the lymph nodes that may be discharged from the tumor. I was able to do it.
Since 2013, IRNA has reported that the United States is the only manufacturer of radioactive drugs.
The lymph system is known as one of the main conduit of cancer metastasis. In patients with breasts, lungs, and genital cancers, accurate detection of lymph nodes is important for surgeons.
If the lymph nodes related to the surgeon cannot be identified in time, it is necessary to remove most of the lymph. This procedure not only has many side effects in patients, but also have a serious effect on immune system and blood circulation.
This radiation diagnostic agent helps a doctor to find a lymph nodes to remove healthy lymph and remove during surgery without having to affect it, and prevent unnecessary surgery and complications.
Thanks to this amazing achievement, about 90 % of patients with various cancers in Japan can access more accurate and accurate methods for diagnosis and treatment of cancer.
After passing the former clinical minister normally, the drug entered the clinical phase.
Cancer, one of the global health issues, affects many people’s lives every year. According to the Ministry of Health, they are the main causes of domestic premature birth deaths.
They have more than 55,000 deaths a year. Approximately 34,000 deaths out of 122,000 early death (under 70,000 years) and 11,000 deaths out of 85,000 very early death (under 50) are caused by various cancers.
The latest national cancer census is expected to increase the number of new cancer cases in Iran to 160,000 by 1404 (March 2025) by the Iranian calendar (March 2025). It is shown.
The most common cancer in Iran is breasts, prostate, colon, stomach, lungs, bladder, thyroid gland, uterus, brain, and spine.
Iran’s most common cancer includes breast, colon, thyroid, stomach, uterus, leukemia, ovaries, brain and spine, lungs, and esophagus.
Currently, about 250,000 Iranians live with cancer. Most of the cancer can be treated and the rest can be avoided.
Recent results
On January 20, 2024, Iranian University (IUMS) has announced the development of a system based on artificial intelligence (AI) that can detect breast cancer with 94 % accuracy.
In Iran, breast cancer is almost the same as the global average, about 30 % of patients die every year, causing women’s second death.
Pre -detection of cancer enhances the possibility of treatment and success.
Iranian -based companies have also announced that they are ready to meet the needs of North Africa, a napuloma (HPV) vaccine. HPV is known to cause cervical cancer in women.
This product is manufactured at 75 % cheaper at a much lower price compared to foreign samples.
The production of HPV vaccines requires one of the most complex technologies in the world, and Iran has been able to produce vaccines in Japan.
When vaccines proved safety and effectiveness in increasing antibody focus, the approval of food and drugs to enter the market in 2020 was obtained.
In September 2023, Iranian -based companies succeeded in producing Iburtinib, which were used to treat various blood cancer, and made the country the third most producer in the world.
IRNA reports that Iran, India, and China are now the only three countries in the world with high -tech knowledge to produce Iburucinib and the necessary raw materials.
mt/mg